Human Genome Sciences Inc (HGSI): Today's Featured Health Care Winner

Human Genome ( HGSI) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day up 0.2%. By the end of trading, Human Genome rose 9 cents (0.7%) to $13.62 on light volume. Throughout the day, 1.8 million shares of Human Genome exchanged hands as compared to its average daily volume of 6.2 million shares. The stock ranged in a price between $13.45-$13.69 after having opened the day at $13.52 as compared to the previous trading day's close of $13.53. Other companies within the Health Care sector that increased today were: Medgenics ( MDGN), up 43%, Rexahn Pharmaceuticals ( RNN), up 29.5%, EntreMed ( ENMD), up 24%, and Coronado Biosciences ( CNDO), up 20%.

Human Genome Sciences, Inc. operates as a biopharmaceutical company in the United States. Its principal products include BENLYSTA for systemic lupus erythematosus; and raxibacumab for inhalation anthrax. Human Genome has a market cap of $2.7 billion and is part of the drugs industry. Shares are up 83.1% year to date as of the close of trading on Tuesday. Currently there are six analysts that rate Human Genome a buy, no analysts rate it a sell, and 14 rate it a hold.

TheStreet Ratings rates Human Genome as a sell. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity, generally disappointing historical performance in the stock itself and generally weak debt management.

On the negative front, Sunshine Heart ( SSH), down 16.4%, Natural Alternatives International ( NAII), down 15%, Cardiome Pharma Corporation ( CRME), down 13.2%, and CombiMatrix Corporation ( CBMX), down 11.4%, were all losers within the health care sector with Biogen Idec ( BIIB) being today's health care sector loser.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).